Floatz logo

Crizotinib

Non-small Cell Lung Cancer

Nuvation Bio Inc.Small moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
59/ 100

Competitive context

1205 Active assets in the Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Crizotinib is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
inflammatory myofibroblastic tumorDormant
BB
Indicative ·
69 / 100
View asset →
ALK-positive anaplastic large cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →